The Latest Cardiac and Vascular News
New software enhances CT image quality across scanner generations, supporting radiologists with improved image clarity and consistency MENLO PARK, Calif., June 10, 2026 /PRNewswire/ — Subtle Medical, a leader in AI-powered medical imaging software, today announced FDA clearance for SubtleHD™(CT), an AI-powered image enhancement solution designed to reduce noise and improve low contrast […]
ATLANTA, June 10, 2026 /PRNewswire/ — Huxley Medical, a commercial-stage medical technology company expanding access to sleep apnea testing across health systems, cardiology, and primary care, today introduced two additions to its SANSA® platform: SANSA GO™, a point-of-care enrollment…
IRVINE, Calif., June 10, 2026 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of the Trilogy® Transcatheter Heart Valve (THV) System, today announced the appointment of Matt Bacso, as Chief Financial Officer, effective June 8, 2026. Matt will lead the company’s financial organization and capital markets activities as JenaValve advances its U.S. commercial launch of the Trilogy System for high risk, symptomatic, severe aortic regurgitation (ssAR). His appointment further strengthens the company’s executive leadership team during a pivotal period of organizational growth and commercial expansion in the United States.
The premier academic health system makes a foundational infrastructure decision to transform radiology reporting, embracing the next era of diagnostic medicine NEW HAVEN, Conn. and SAN FRANCISCO, June 10, 2026 /PRNewswire/ — Rad AI, the leader in AI-powered radiology workflow solutions,…
The same clinician-approved animations from the Hx Heart app are now available online at HxHeart.com — free, instantly, with no download required. BERKELEY, Calif., June 9, 2026 /PRNewswire/ — Medmovie, Inc., creators of the Hx Heart app, announced that its cardiovascular education…
OAK BROOK, Ill., June 9, 2026 /PRNewswire/ — Three commercially available radiology AI systems have shown the potential to flag early signs of breast cancer up to 6 years before a diagnosis, according to a study published in Radiology, the flagship journal of the Radiological Society of…
CHICAGO–(BUSINESS WIRE)–GE HealthCare will showcase its latest enterprise imaging solutions at the Society for Imaging Informatics in Medicine (SIIM) 2026 Annual Meeting in Pittsburgh, PA. Medical imaging departments today are under immense pressure from all sides including rising imaging volumes and increasing case complexity, while staffing shortages continue to grow. According to the American College of Radiology (ACR), radiologist workforce shortages have been identified as the biggest th
Microbot Medical® Announces a Notable Health System as the First in Michigan to Adopt the LIBERTY® Endovascular Robotic System
SUNNYVALE, Calif.–(BUSINESS WIRE)–EBR Systems, Inc. (ASX: EBR), developer of the world’s only leadless left ventricular endocardial pacing (LVEP) system for heart failure, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has initiated a National Coverage Determination (NCD) to evaluate uniform Medicare coverage for leadless LV endocardial pacing used in cardiac resynchronization therapy (CRT). The initiation of the NCD process is a key outcome of EBR’s engageme
MINNEAPOLIS, June 09, 2026 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Jared Oasheim, the Company’s Chief Financial Officer, will be stepping down from his role to pursue other professional opportunities. To support a seamless transition, Mr. Oasheim will remain with the Company until a successor is appointed and remain available as an advisor through February 2027.“Jared has been an integral part of CVRx since 2015, and has made a lasting mark on our company over the past decade” said Kevin Hykes, President and Chief Executive Officer of CVRx. “He led CVRx through its initial public offering and built the disciplined finance organization that supports our commercial growth today, all while staying focused on our mission to improve the lives of patients with heart failure. We are grateful for his many contributions and wish him every success.”“It has been a privilege to help build CVRx alongside such a dedicated team and to play a part in bringing Barostim to more patients,” said Jared Oasheim, Chief Financial Officer of CVRx. “Taking the company public and helping establish its financial foundation has been one of the highlights of my career. I am committed to a seamless transition and look forward to seeing CVRx continue its momentum.”The Company is initiating a search to identify its next Chief Financial Officer.Presentation at Goldman Sachs Healthcare ConferenceAs previously announced, Kevin Hykes and Jared Oasheim will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on Wednesday, June 10, 2026 at 8:00 a.m. (ET). A live webcast of the event can be found at ir.cvrx.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.About CVRx, Inc.CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.Investor Contact:Mark Klausner or Mike VallieICR Healthcare443-213-0501ir@cvrx.comMedia Contact:Emily MeyersCVRx, Inc.763-416-2853emeyers@cvrx.com
